For adult patients with active psoriatic arthritis (PsA)
ADEPT was a 24-week randomized, double-blind, placebo-controlled study in 313 adult patients with active PsA who had inadequate response to NSAIDs. Co-primary endpoints were ACR 20 response at week 12 and mean change from baseline in mTSS for HUMIRA-treated patients at week 48 vs placebo at week 24. Patients who completed the original 24-week double-blind ADEPT study (n=285) were eligible for open-label treatment through week 144.1-4
HUMIRA 40 mg EOW (n=151)
Improvement is measured in this trial by a mean percentage decrease from baseline of HAQ-DI scores.
The 8 category scores are averaged to obtain the HAQ-DI score, which ranges from 0 to 3, with a higher score indicating a greater extent of functional limitations.